国产a级特黄的片子,精品香蕉一区二区三区,亚洲精品99久久久久中文字幕,无码精品A∨在线观看无广告

Stock(600222)Hot line:010-61006450

MAH

Leader of "0" Cost MAH 3.0 Era

Platform Overview

Platform Overview
————???????—???????—???????—???????—???????—???????—

 
The project Initiation service platform has more than 20 professional knowledge personnel, all from Shenyang Pharmaceutical University, Chinese Academy of Medical Sciences, Peking Union Medical College and other well-known universities at home and abroad, and has set up generic drug project strategy center, clinical & pharmacology center, intellectual property center, big data analysis center, international new product strategy center, based on the all-round analysis of the pharmaceutical industry and combined with the company's own differentiated positioning, can provide customers with personalized information technology services and comprehensive information assurance.

 Service Content

—???????—???????—???????—???????—???????—???????—???????—???????—???????—

1) Generic Drug Project Initiation: Project development risk assessment is carried out through comprehensive analysis of listed product information, including review overview, patents, market prospects, competition pattern, technical barriers, policy dynamics and other mainstream regulatory countries in Europe, the United States, Japan, China, Canada, Australia and other mainstream regulatory countries.
???????

2)Improvement and Innovation Projects: According to the domestic clinical needs and the guidance of policies and regulations, look for potential improvement and innovation projects, conduct comprehensive research from the aspects of product clinical positioning, market value, competition dynamics, patent layout, and development and listing paths of such projects at home and abroad, determine the adequacy and feasibility of the basis for the topic, and conduct in-depth pharmaceutical technology evaluation, clinical evaluation, development cycle and cost evaluation of the proposed development project.
 

3) Strategy Consulting Service: According to the needs of enterprises, provide partners with product pipeline sustainable development planning, feasibility analysis of new entry fields, and R&D strategy formulation after policy changes, such as the development opportunities and challenges in the cardiovascular field, the key points of improved new drug technology research and development, the analysis of the clinical drug competition pattern of platforms (ophthalmic preparations, enteric-coatedpreparations, sustained-release preparations), and the monthly analysis report of CDE application acceptance products.
 

4)Patent Service: Patent layout of cooperation projects, patent risk assessment of new products, infringement analysis and circumvention strategies, patent search and analysis service, patent tracking and early warning analysis.

5)Resource sharing: The leadingpharm information department cooperates with many well-known pharmaceutical databases at home and abroad (cortellis, intranet, insight, wisdombud), which can provide domestic and foreign listing information, the latest information on industry policies, new products/targets at home and abroad, domestic and foreign product sales and forecast data, market access, clinical guidelines and clinical front-line drug consultation, etc.


 

 

 

 

 

 

 

人妻av无码专区久久绿巨人| 伊人色综合久久天天五月婷| 亚洲av永久精品无码桃色| 国产精品美女久久久久浪潮av| 亚洲精品无码久久毛片| 亚洲国产精品一区二区www| 久久久精品| 久久婷婷五月综合色国产香蕉 | 亚洲av无码无在线观看红杏| 蜜桃狠狠色伊人亚洲综合网站| 国产大学生粉嫩无套流白浆| AV一区二区三区人妻少妇| 小少妇性开放xxxxxhd| 久久久久亚洲av无码永不 | 国内老熟妇对白hdxxxx| 久久久久蜜桃精品成人片| 久久午夜无码鲁丝片秋霞| 凡人修仙传动漫在线观看| 国产一二三精品无码不卡日本| 久久久av男人的天堂| 狠狠色婷婷久久一区二区三区 | 99精品无码一区二区毛片免费| 国产精品久久| 国产乱码精品一区二区三区香蕉 | 欧美在线香蕉在线视频| 亚洲一区二区三区av无码| 性一交一乱一色一视频| 久久亚洲私人国产精品va| 精品人妻无码区二区三区| 亚洲av无码乱码在线观看性色扶 | 欧美老妇大p毛茸茸| 亚洲欧美日本韩国| juliaann精品艳妇| 亚洲中文字幕无码亚洲人成影院| 老师课后辅导乳揉搓h在线观看| 欧美+日本+国产| 亚洲熟伦熟女专区hd高清| 久久人人爽人人人人爽AV| 在线播放亚洲第一字幕| 国产日产久久高清欧美一区| 中国大陆高清aⅴ毛片|